C12557: CARDIAC INJURY DIAGNOSTIC BIOMARKERS
Invention novelty:
Biomarkers identified for accurate and differential diagnosis and prognosis of cardiac injury and associated delayed adverse event related risks
Value Proposition:
Currently, various tests have been used to detect myocardial events. The clinically available tests include assays for measuring the levels of troponin and creatine kinase; markers of cardiac injury. However, apart from troponin, none of these markers are cardiac specific. Moreover, there are sensitivity and specificity issues with these tests. Therefore, all current clinical tests are not completely satisfactory for accurate and differential diagnosis and prognosis of cardiac injury. The new markers described here can be used in conjunction with other clinical available assays such high-sensitive troponin assays, myoglobin, CK-MB total and isoforms types of assays. These novel markers have a number of advantages including:
• Early, accurate and differential diagnosis of cardiac injury from cardiac ischemia
• Facilitate differentiation of the types of Acute Coronary Syndrome and identify individuals at risk for delayed adverse events.
• Facilitate prognostic disease management and risk stratification.
Technical Details:
Johns Hopkins researchers have identified a panel of biomarkers that can help in the differential diagnosis and prognosis of cardiac injury. They have conducted tests on the panel of biomarkers and have differentiated them into cardiac injury biomarkers and cardiac injury related biomarkers. They have conducted these studies using the valve replacement model. Upon identification, these markers were validated for cardiac injury by conducting various tests.
Looking for Partners: To develop and commercialize the technology as a kit for detecting the presence of cardiac injury in a subject.
Stage of Development: Pre-Clinical
Publication(s)/Associated Cases: Not at this time
